Skip to main content

What the FDA labels say about taking them together

Diltiazem and dronedarone

Dronedarone's FDA label of May 29, 2025 names diltiazem in its drug interactions section; the diltiazem labels PlainMeds reads (4) do not name dronedarone. The dronedarone label: “Calcium Channel Blockers Verapamil and diltiazem are moderate CYP3A inhibitors and increase dronedarone exposure.”

Check it at the source: the diltiazem FDA label on DailyMed (effective August 7, 2026, Bausch Health US, LLC); the dronedarone FDA label on DailyMed (effective May 29, 2025, Sanofi-Aventis U.S. LLC).

What does the diltiazem label say about dronedarone?

Diltiazem's label (effective August 7, 2026) and its 3 other brand-application labels do not name dronedarone in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (TIAZAC EXTENDED RELEASE), Bausch Health US, LLC, effective August 7, 2026 (SPL set c567fe7e-887e-4291-a0d1-2dd3f25cbf25), via openFDA; the full label on DailyMed

What does the dronedarone label say about diltiazem?

Dronedarone label, drug interactions

Calcium Channel Blockers Verapamil and diltiazem are moderate CYP3A inhibitors and increase dronedarone exposure.

Source: FDA drug label (Multaq), Sanofi-Aventis U.S. LLC, effective May 29, 2025 (SPL set 7fa41601-7fb5-4155-8e50-2ae903f0d2d6), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

50Diltiazem generic labelers
0Dronedarone generic labelers
DiltiazemDronedarone
Labeled forHigh blood pressure, Angina, Atrial fibrillationn/a
Boxed warningNoYes
Pharmacy cost (NADAC)$0.144 per capsule 24h ER(cd) 120 mg capsule$13.19 per tablet 400 mg tablet
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?